- About Us
- Services & Solutions
- WuXi XDC – Bioconjugation
- News & Media
Offering End-to-End Solutions
State-of-the-art facility, encompassing 200,000 sq. ft., has been operational since 2018.
Site offers comprehensive, integrated one-stop biologics CMC development and GMP manufacturing services in one central location.
Facility houses 10 European Medicines Agency (EMA)-certified GMP cell banking suites.
1.6 million sq. ft. global innovation site to be operational in 2021
New state-of-the-art facilities providing discovery, development, analytical development and QC testing and pilot and clinical-scale GMP manufacturing capabilities in one location
Multiple facilities with a total area of 160,000 sq. m.
Early and late-stage development laboratories and clinical and commercial-scale drug substance and drug product GMP manufacturing
First facility in China approved by the U.S. FDA and EMA for production of a commercial antibody therapeutic
Facility dedicated to the development and GMP manufacture of Antibody Drug Conjugates (ADCs) and other bioconjugates. Facility footprint encompasses nearly 6,000 square meters.
Site provides integrated services and solutions including process development, technology transfer, and pilot scale to large-scale cGMP production of drug substance and drug product.
State-of-the-art facility houses an advanced, fully-isolated automatic aseptic filling system which can fill 2R, 6R, 10R, 20R and 50R vials for either liquid or lyophilized products. With ability to provide three million doses annually, system provides the flexibility to meet production requirements for both global clinical trials and commercial product launch.
Site is part of WuXi XDC, a WuXi Biologics subsidary, that offers extensive and comprehensive set of in-house capabilities to handle all stages of ADC drug development, including development and manufacture of payload-linkers and antibody or other biological intermediates.
Site opened in December 2014
Over 10,100 sq. m. testing facility was the first non-government affiliated biosafety testing facility in Asia
Facility performs cell line characterization, viral clearance validation studies and unprocessed bulk lot release
Acquired CMAB Biopharma Group to build MFG21 and DP11
Cell line engineering and process development laboratories
Drug substance capacity: 7,000L
Liquid and lyophilization drug product fills available
Operational since 2020 this multi-facility site will be GMP-ready in 2021
Home to facilities dedicated to the development and GMP manufacture of recombinant proteins and plasmid DNA produced via microbial fermentation
Separate facilities available for the development and GMP production of viral-based vaccines
50,000 sq. m. facility, operational since 2018 available for GMP Production in H2 2021
Acquired site as well as its labor force from Pfizer China (“Pfizer”) in March 2021.
Drug substance capacities: 2 x 2,000L and expandable to 4 x 2,000L
Liquid or lyophilized drug product fills into vials and pre-filled syringes at 10 million units/year and 1 x 10m2 lyo capacity
Planned to open in 2023 this 314,000 sq. m. (1.3 million sq. ft.) multi-facility site will be the largest CDMO site in western China
New integrated manufacturing center will include drug research and development and commercial-scale drug substance manufacturing facilities with initial bioreactor capacity of 48,000 L
Planned 82,160 sq. m. facility will be one of the largest CDMO facilities in northern China
New biologics center will house development laboratories and a biologics commercial-scale drug substance manufacturing facility with initial bioreactor capacity of 48,000 L
Operations to commence in 2022
Invested $60 Million to provide facilities for early stage bioprocess development and clinical-scale GMP manufacture
Operations expected to commence in 2023
Over 45,000 sq. m. facility resides on 26-hectare site acquired in April 2018 and was supported by by the Irish Government through IDA Ireland
This“Factory of the Future” will provide biologics commercial-scale GMP manufacturing
Drug Substance GMP manufacturing to commence in 2022
WuXi Vaccines will construct a purpose-built vaccine manufacturing facility adjacent to the WuXi Biologics “Factory of the Future.”
Operations to commence in 2022
Over 13,000 sq. m. commercial-scale drug product fill facility
Site acquired in June 2020 from Bayer
Liquid and lyophilization annual fill capacity of 10 million doses
Site utilizes flexible isolator-based and state-of-the-art Optima filling system that includes associated vial washer, depyrogenation tunnel, stoppering and capping units, automated loading/unloading system and 2 x 23 sq. m. freeze dryers (lyophilizers)
Multiple vial CCS sizes range from 2R to 50R
State-of-the-art 30,000 sq. m. Drug Substance(DS) facility acquired from Bayer in December 2020
Two cell culture suites with 3 x 1000L perfusion and 6 x 2000L fed-batch bioreactor capacity and independent downstream area with pre- and post-viral filtration purification suites
38 km （30 minutes driving） from the WuXi Biologics Drug Product facility in Leverkusen (DP7, another facility acquired from Bayer) – both sites will support WuXi Biologics’ Global Dual Source supply chain network strategy
Flexible and open spaces available for future expansion
Expected to be GMP-ready in Q4 2021
Site ground breaking in June 2020 for 107,000 sq. ft. facility
State-of-the-art single-use technology facility is located in the world’s top biotech hub
Site dedicated to biologics GMP clinical- and commercial-scale manufacturing
Operations to commence in 2024
Facility focused on biologics development and drug substance GMP clinical-scale manufacturing
Over 66,000 sq. ft. facility located in the robust biopharmaceutical tristate region of NY, NJ and PA
Site operations to start in 2021
More than 33,000 sq.ft. of Biosafety Level 2 laboratories
Site operations started in October 2020